WST - West Pharmaceutical's 2024 Outlook Cautious Analysts Remain Optimistic | Benzinga
West Pharmaceutical Services Inc’s (NYSE:WST) fourth-quarter 2023 adjusted EPS came in at $1.83, up 3.4% Y/Y, beating the consensus of $1.78.
Quarterly sales reached $732 million, up 3.3%, missing the consensus estimate of $739.47 million. Organic net sales growth was 1.4%.
“In 2024, we expect moderated organic sales growth as we manage timing of inventory management, especially with our largest customers. We expect headwinds to be more pronounced during the first quarter and less impactful in subsequent quarters. I am pleased that our February order book for the second half of the year is outpacing typical pre-pandemic levels, coupled with customer optimism of certain breakout drug categories and timing of additional high-value product device capacity, all ...